Ascendis Pharma A/S (NASDAQ:ASND) Given New $153.00 Price Target at TD Cowen

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective reduced by TD Cowen from $160.00 to $153.00 in a report issued on Friday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

Several other equities research analysts have also weighed in on the stock. Wedbush reiterated an “outperform” rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a report on Friday. Stifel Nicolaus upped their price target on Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a research report on Friday. StockNews.com cut Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a report on Tuesday. The Goldman Sachs Group raised their target price on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. Finally, Oppenheimer reduced their price target on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a report on Friday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $191.77.

Ascendis Pharma A/S Stock Up 1.8 %

NASDAQ:ASND traded up $2.23 during trading hours on Friday, hitting $126.51. 1,448,861 shares of the stock were exchanged, compared to its average volume of 450,130. Ascendis Pharma A/S has a twelve month low of $90.13 and a twelve month high of $161.00. The company has a market capitalization of $7.67 billion, a P/E ratio of -13.59 and a beta of 0.66. The company’s 50 day moving average is $132.30 and its two-hundred day moving average is $132.70.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The company had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. On average, equities research analysts expect that Ascendis Pharma A/S will post -7.35 EPS for the current year.

Institutional Trading of Ascendis Pharma A/S

Institutional investors have recently modified their holdings of the stock. Groupama Asset Managment acquired a new position in Ascendis Pharma A/S during the third quarter valued at approximately $60,000. Signaturefd LLC raised its position in shares of Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 80 shares in the last quarter. Bessemer Group Inc. increased its holdings in Ascendis Pharma A/S by 61.0% in the first quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 332 shares in the last quarter. Searle & CO. acquired a new position in shares of Ascendis Pharma A/S during the 2nd quarter valued at $205,000. Finally, Rhumbline Advisers raised its holdings in shares of Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 143 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.